DO-BO

Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel?

In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR “notified body bottleneck” is largely yesterday’s problem, and how smart startups build regulatory timelines, costs, and clinical evidence into their plans from day one.

They then zoom out to Omnibus, the AI Act, and geopolitics, and what all of this means for the attractiveness of Europe vs. the US, China, India, and the rapidly growing Arabic region as medtech markets. Despite the challenges, Europe still offers world‑class innovation, strong universities, and a powerful SME ecosystem – and remains a key region for medtech investment. If you’re a medtech founder, regulatory lead, or market access professional, this episode will help you rethink when and how you integrate regulation and reimbursement into your strategy.

Related

By the time most health economists get pulled in, the recipe is already set. In this episode of MAP — the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist […]

This is a repost of a popular episode of MAP – Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a […]